| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net income / (loss) | 2,154 | -8,833 | 50,180 |
| Change in gain on sale of business | -344 | -3,439 | 60,435 |
| Depreciation and amortization | 3,060 | 3,008 | 5,177 |
| Stock-based compensation | 5,035 | 6,586 | 11,246 |
| Change in fair value of warrant liabilities | -1,459 | -1,416 | -2,862 |
| Change in fair value of other assets and liabilities | -3,444 | 1,037 | NaN |
| Excess of lease liability over operating right-of-use assets | NaN | 0 | 0 |
| Transaction costs paid related to sale of business | NaN | 1,417 | 5,964 |
| Gain on lease modification | NaN | 0 | NaN |
| Acquisition consideration allocated to seller transaction expenses | NaN | 0 | 44,339 |
| Impairment of intangible assets | NaN | 0 | 0 |
| Impairment of property and equipment | NaN | 1,673 | NaN |
| Realized loss from sale of short-term investments | NaN | 0 | -5,195 |
| Realized foreign exchange gain | NaN | 0 | 798 |
| Accretion of interest income on held-to-maturity securities | 265 | 482 | 1,732 |
| Deferred tax expense | -77 | -126 | 558 |
| Other Operating Activities Cash Flow Statement | 27 | 83 | 388 |
| Prepaid expenses and other current assets | -383 | 2,462 | -776 |
| Accounts receivable | -149 | 3,483 | 8,551 |
| Other non-current assets | -78 | 0 | -666 |
| Operating right-of-use assets/lease liabilities | -73 | -2 | 90 |
| Accounts payable and accrued expenses | -2,158 | -6,017 | 8,395 |
| Deferred revenue | -3 | 1,684 | NaN |
| Other current liabilities | NaN | NaN | 1,583 |
| Increase Decrease In Other Operating Capital Net | 12 | NaN | NaN |
| Net cash provided by/ (used in) operating activities (includes discontinued operations see note 4) | 3,885 | -8,307 | -40,607 |
| Acquisitions, net of cash acquired | NaN | 1,361 | 65,174 |
| Cash transfer related to sale of business | 290 | 1,569 | 1,241 |
| Capitalized software development costs | 302 | 157 | 1,258 |
| Purchase of property and equipment, net of proceeds from disposal | 5,179 | 1,848 | 7,747 |
| Purchase of held-to-maturity investments | 0 | 0 | 146,258 |
| Proceeds from maturities of held-to-maturity investments | 30,500 | 23,200 | 203,000 |
| Proceeds from sale of short-term investments | NaN | 0 | 70,163 |
| Net cash provided by investing activities (includes discontinued operations see note 4) | 24,729 | 18,265 | 51,485 |
| Proceeds from the exercise of common stock options | 52 | 54 | 139 |
| Taxes paid related to net share settlement of equity awards | 582 | 1,796 | 7,309 |
| Repurchase and retirement of common stock | NaN | 0 | 0 |
| Payments for debt issuance costs | 329 | NaN | NaN |
| Net cash used in financing activities (includes discontinued operations see note 4) | -859 | -1,742 | -7,170 |
| Effect of foreign exchange rate changes on cash balances | 0 | 0 | -339 |
| Net increase in cash and cash equivalents and restricted cash | 27,755 | 8,216 | 3,369 |
| Cash and cash equivalents and restricted cash - beginning | 31,232 | -3,369 | 19,647 |
| Cash and cash equivalents and restricted cash - ending | 58,987 | 8,216 | 23,016 |
Strata Critical Medical, Inc. (SRTA)
Strata Critical Medical, Inc. (SRTA)